Previous Article | Next Article 
J Virol, May 1998, p. 3952-3957, Vol. 72, No. 5
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Transmission of Human T-Cell Leukemia Virus Type 1 to Mice
Jianhua
Fang,
Shigeki
Kushida,
Renqing
Feng,
Masakazu
Tanaka,
Tomonori
Kawamura,
Hideaki
Abe,
Naoyoshi
Maeda,
Makoto
Onobori,
Mituo
Hori,
Kazuhiko
Uchida, and
Masanao
Miwa*
Department of Biochemistry and Molecular
Oncology, Institute of Basic Medical Sciences and Center for Tsukuba
Advanced Research Alliance, University of Tsukuba, Tsukuba, Ibaraki
305, Japan.
Received 15 September 1997/Accepted 9 February 1998
 |
ABSTRACT |
Human T-cell leukemia virus type 1 (HTLV-1) is associated with
adult T-cell leukemia/lymphoma, HTLV-1-associated myelopathy/tropical spastic paraparesis, and other diseases. For prevention of the transmission of HTLV-1 and manifestation of these diseases, a small-animal model, especially a mouse model, would be useful. We
injected HTLV-1-producing T cells (MT-2) intraperitoneally into
neonatal C3H/HeJ mice. While the antibody against HTLV-1 antigens was
not detectable in C3H/HeJ mice, HTLV-1 provirus was frequently detected
in the spleen, lymph nodes, and thymus by PCR. HTLV-1 provirus was
present at the level of 0 to 30 molecules in 105 spleen
cells at the age of 15 weeks. In addition, a 59-bp flanking sequence of
the HTLV-1 integration site was amplified from the spleen DNA by
linker-mediated PCR and was confirmed to be derived from the mouse
genome. HTLV-1 provirus was found in the T-cell fraction of the mouse
spleen. These results indicate that mice can be infected by HTLV-1 and
could serve as an animal model for the study of HTLV-1 infection and
its pathogenesis in vivo.
 |
INTRODUCTION |
Human T-cell leukemia virus type 1 (HTLV-1) is known to be associated with the pathogenesis of adult
T-cell leukemia (ATL) (5, 8, 29, 30, 39, 44),
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
(6, 28), HTLV-1-associated arthropathy (26, 31),
HTLV-1-associated uveitis (25), and HTLV-1-associated
bronchopneumopathy (45). Transmission of HTLV-1 via blood
can be prevented by anti-HTLV-1 antibody screening, which was started
in Japan in 1987 (13). The main route of HTLV-1 transmission
is now from mother to child (7, 37). Therefore, the majority
of HTLV-1 carriers are those who were infected with HTLV-1 in
childhood. Only a small percentage of carriers of HTLV-1 are patients
with HTLV-1-associated diseases (36). In addition, there is
a long latency period before manifestation of HTLV-1-associated diseases (14, 38). The pathophysiological status of these carriers is not well understood. These facts make analysis of the
pathogenesis of HTLV-1-associated diseases and their prevention difficult. For analysis of the pathophysiology of HTLV-1 carriers, a
small-animal model of HTLV-1 infection is useful. Such a model can also
be helpful for the development of therapeutics and protective measures
against the HTLV-1-associated diseases.
The transmission of HTLV-1 in animals has been reported for rabbits
(1, 18, 32, 40) and monkeys (15, 42, 43). Previously, we succeeded in establishing persistent infection with
HTLV-1 in rats (34). We and others showed HAM/TSP-like paraparesis in WKA rats (11, 20). Mice have some advantages over other animal models, because more information on genetics and on
biological techniques for working with embryos is available for mice
(3, 12). In addition, the dose of reagents and the space
required should be less than for monkeys and rabbits. In this work, we
report on a mouse model of HTLV-1 infection by intraperitoneal injection of HTLV-1-producing human T cells into newborn C3H/HeJ mice.
(A preliminary report of this work has been presented previously
[19]).
 |
MATERIALS AND METHODS |
Cells.
An HTLV-1-producing human T-cell line, MT-2
(24), was cultured in RPMI 1640 medium supplemented with
10% fetal calf serum.
Animals.
Pregnant C3H/HeJ mice were purchased from Clea,
Inc., Tokyo, Japan. Twenty-nine C3H/HeJ offspring born to four
dams were each injected intraperitoneally with 2.5 × 106 MT-2 cells within 24 h after birth and again at
the age of 1 week. After injection, two offspring were lost by maternal
cannibalism and nine offspring were lost by accidents in blood sampling
and were not analyzed. Two offspring at the 7th week and 5 offspring at
the 11th week were dead at the time of blood sampling, and at the 15th
week, 11 offspring were sacrificed after ether anesthesia. Finally,
these 18 offspring were analyzed for provirus detection.
PCR.
DNA from peripheral-blood mononuclear cells (PBMC) of
the mice was prepared by using a QIAamp Blood Kit (Qiagen, Hilden,
Germany). DNA from the thymus, lung, liver, spleen, kidney, and
peritoneal lymph nodes was prepared by sodium dodecyl
sulfate-proteinase K digestion, followed by phenol extraction. One
microgram of DNA was used in each PCR. Detection of the pX
sequence of HTLV-1 provirus was performed by PCR and Southern blot
analysis as described previously (21, 22, 34). A duplicate
PCR was performed with the same DNA (Fig. 1 and 2; Tables 1 and 2). The
c-myc sequence of the mouse was amplified in the reaction
tube used for multiplex PCR. Visualization of the c-myc band
in the gel serves as an internal control to confirm the quality of
template DNA and the conditions for successful PCR (21, 34).
We also examined the human endogenous retrovirus R (HERV-R) sequence
(27) by PCR in order to exclude the possibility of MT-2
cells remaining in MT-2 cell-injected animals (34).
Amplification of the integration sites of HTLV-1 by linker-mediated PCR
was carried out according to the procedure described by Wattel et al.
(41) with slight modifications (reference
4 and unpublished data).
Statistical analysis.
The probability of frequencies for
detecting pX and HERV-R sequences was calculated by Poisson
distribution, and the parameters were estimated by the maximum
likelihood method.
Antibody detection.
The antibodies against HTLV-1 proteins
(mainly Gag; in part, Env) in the plasma were assayed with a particle
agglutination kit (Serodia HTLV-1; Fujirebio, Tokyo, Japan)
(10).
Histological analysis.
The organs of mice were fixed in 4%
cacodylate-buffered paraformaldehyde (pH 7.2). Three-micrometer-thick
paraffin sections were stained with hematoxylin and eosin and were
examined microscopically.
Analysis of mRNA for pX.
RNA was extracted from three
mice at the age of 16 weeks with the ISOGEN kit (Nippongene, Osaka,
Japan). RNA from MT-2 cells was used as a positive control. The primers
used were RPX3 and RPX4, described by Kinoshita et al. (16).
One-half microgram of RNA was used for reverse transcription-PCR
(RT-PCR) analysis. Reverse transcription was performed with Moloney
murine leukemia virus reverse transcriptase. PCR was performed with
Ampli Taq Gold (Perkin-Elmer), with 50 cycles of amplification
reaction.
Cell sorting by flow cytometry.
For cell sorting, two
C3H/HeJ mice injected with MT-2 cells (mouse 2 and mouse 3) were used.
They were sacrificed at the age of 12 weeks. Splenocytes from MT-2
cell-injected mice were prepared and doubly stained with
phycoerythrin-labeled rat anti-mouse B220 immunoglobulin G2A (IgG2a)
and fluorescein isothiocyanate-labeled hamster anti-mouse CD3e IgG
(both from PharMingen). In order to exclude dead cells, 1 µg of
propidium iodide/ml was added and fractionated with a flow cytometer
(FACS VANTAGE; Becton Dickinson). The cells with high expression of
B220 or CD3e were sorted as B-cell and T-cell fractions, respectively,
and aliquots of 105 cells per tube were collected. The
cells were washed with phosphate-buffered saline, and their lysates
were analyzed for HTLV-1 pX sequence by PCR and Southern
hybridization.
Nucleotide sequence accession number.
The sequence data
shown in Fig. 3 for a part of the 3' long terminal repeat (LTR) and its
flanking mouse genomic sequence are available in the GenBank database
under accession no. AF005373.
 |
RESULTS |
Sensitivity of detection of HERV-R, pX,
gag, and LTR sequences by PCR.
We checked the
sensitivity of detection of pX and HERV-R sequences by
PCR-Southern blot analysis using a serial dilution of MT-2 cell DNA
with normal mouse spleen DNA, since we injected MT-2 cells into mice.
The HERV-R sequence was detectable down to 1 MT-2 cell equivalent of
DNA, which should contain four molecules of LTR of HERV-R in one
diploid human cell (27) in the reaction mixture (Fig.
1a). We detected pX sequence
from a minimum of 0.1 MT-2 cell equivalent of DNA (Fig. 1b), which
should contain 0.6 molecule of pX sequence, since 6 molecules of pX sequence are reported to be present in each
MT-2 cell (17). Our results confirmed that one molecule of
pX sequence in the reaction tube is detectable in our PCR
system. Since gag and 5' LTR are mostly defective in MT-2
cells (17), we used ATL-1K cells, each of which contains one
complete molecule of HTLV-1 provirus (9), as the standard for detection of gag and LTR sequence. As shown in Fig. 1c,
gag was detectable to the level of 0.3 to 1 ATL-1K cell
equivalent of DNA, indicating that one molecule of gag is
detectable. LTR was detectable to 1 ATL-1K cell equivalent of DNA,
indicating that one to two molecules of HTLV-1 LTR are detectable (Fig.
1d). Visualization of the amplified mouse c-myc sequence
indicates that the PCR conditions were satisfactory (Fig. 1a).

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 1.
Sensitivity of PCR for detecting HERV-R, pX,
gag, and LTR sequences. The PCR templates were prepared so
that DNA from 0 to 100 MT-2 (a and b) or ATL-1K (c and d) cells is
contained in a tube by dilution with normal mouse spleen DNA, keeping
the total DNA content at 1 µg in each reaction. One microgram of DNA
is calculated to correspond to 105 cells. (a) A 353-bp
c-myc fragment was amplified from mouse c-myc and
stained with ethidium bromide. A 186-bp HERV-R fragment was amplified
from HERV-R sequence in MT-2 cells and was hybridized with HERV-R probe
(34). DNA, no DNA added in PCR tube; M, DNA size markers,
indicating 502, 398, 299, 200, and 101 bp. (b) A 159-bp pX
fragment was amplified from MT-2 cell DNA that contained six molecules
of pX sequences per cell (17), and this fragment
was hybridized with pX probe (34). (c) A 120-bp
gag fragment was amplified from ATL-1K cell DNA and was
hybridized with gag probe (34). N, normal mouse
spleen DNA. (d) A 269-bp LTR fragment was amplified from ATL-1K cell
DNA and was hybridized with LTR probe (34).
|
|
Detection of HTLV-1 provirus sequence in MT-2 cell-injected
mice.
We analyzed PBMC and several other organs in the mice to
detect HTLV-1 provirus sequence. HTLV-1 pX sequence was
detected both in PBMC (Table 1) and in
the other organs, including the thymus, lung, liver, spleen, kidney,
and lymph nodes, in C3H/HeJ mice (Table
2). gag and pX
sequences in PBMC were detected in 9 and 30% of the mice,
respectively, at the age of 7 weeks, and in 20 and 33% of the mice,
respectively, at the age of 11 weeks. pX sequence was
detected in PBMC in 27% of the mice at the age of 15 weeks (Table 1).
Failure to detect the provirus in PBMC does not necessarily mean that
the provirus is not present in other organs of the same animal (Table
2). The rate of detection of HTLV-1 pX sequence was higher
in the spleen (13 of 18 mice [72%]), the lymph nodes (12 of 18 mice
[67%]), and the thymus (9 of 18 mice [50%]). Every mouse
contained the provirus in at least one organ. The detection rate was
lowest in the liver DNA. No HTLV-1 pX sequence was detected
in PBMC and the other organs of negative-control mice which had not
received MT-2 cells.
Quantitation of HTLV-1 provirus and HERV-R molecules in spleen
DNA.
For quantitation of the provirus molecules, we analyzed
spleen DNA, since we frequently detected the provirus in the spleen (Table 2; Fig. 2a). We diluted the spleen
DNA with normal mouse spleen DNA. pX sequence was detected
in 1- to 30-fold dilutions of the positive DNA samples. We further
analyzed the amount of the pX sequence in the spleen DNA of
mouse 33, since this mouse had the largest amount of provirus in the
spleen DNA. We detected the pX sequence in a 30-fold
dilution of the spleen DNA of mouse 33 (Fig. 2b). The small, irregular
signals in one of the two lanes at a 100-fold dilution are stains that
appeared during Southern hybridization. gag sequence was
detected in 1- to 10-fold dilutions, and LTR sequence was detected in
1- to 100-fold dilutions, of the spleen DNA of mouse 33 (Fig. 2c). No
HERV-R sequence could be detected in the spleen DNA of mouse 33, even
at a onefold dilution (Fig. 2d). From the comparison of the calculated
and observed probabilities of frequencies for detecting pX
and HERV-R sequences in spleen DNA from mouse 33 by Poisson
distribution, the parameter was calculated by maximum likelihood. The
probability of MT-2 contamination in spleen DNA from mouse 33 was
calculated to be 0.0019, which is very low.

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 2.
Detection by PCR of HTLV-1 provirus from spleen DNA of
MT-2 cell-injected mice. (a) Detection of pX sequence in
spleen DNA derived from 11 mice at the age of 15 weeks. Mouse numbers
are the same as in Table 2. P, positive control (DNA from 10 MT-2 cells
diluted with normal mouse spleen DNA amplified by PCR); N, normal mouse
spleen DNA). (b and c) Quantitation of pX, gag,
and LTR sequences in the spleen DNA of mouse 33 (33sp DNA). Spleen DNA
from mouse 33 was diluted with normal mouse spleen DNA, keeping the
total DNA to 1 µg. (d) No human-genome-specific HERV-R was detected
in the spleen DNA of mouse 33. Dilution was carried out as described
above. DNA, no DNA added; M, DNA size markers, indicating 502, 398, 299, and 200 bp.
|
|
These results are consistent with the integration of HTLV-1 provirus in
the spleen DNA of mouse 33.
Identification of the flanking sequence of the HTLV-1 integration
site.
To get more direct evidence of the integration of HTLV-1 in
the mouse genome and to show that it is not the contamination of MT-2
cells which might be in the mouse spleen, we isolated the integration
site by linker-mediated PCR as described by Wattel et al.
(41). We used the spleen DNA of mouse 51, since we had used
up most of the spleen DNA of mouse 33. As shown in Fig.
3, we cloned and identified a flanking
sequence of the HTLV-1 integration site. The flanking sequence has no
significant homology to the available database sequences (see
"Nucleotide sequence accession number" under Materials and
Methods). To prove that the integration site is of mouse genome origin,
we designed a primer set, 51F and 51R, as shown in Fig.
4a, to amplify the 59-bp flanking
sequence from the template DNA, using normal mouse spleen DNA or MT-2
cell DNA as the template. The expected 59-bp DNA fragment was amplified from normal mouse spleen DNA but not from MT-2 cell DNA (Fig. 4b). In a
parallel set of PCRs, pX fragment was successfully amplified from MT-2 cell DNA but not from mouse spleen DNA, indicating that the
quality of MT-2 cell DNA is suitable for use as a template (data not
shown). The results show that the flanking sequence is derived from the
mouse genome. To further confirm that the cloned sequence was present
as the flanking sequence to the HTLV-1 LTR, PCR was performed with a
forward primer (Bio-2) complementary to a part of the 3' LTR, with 51R
as the reverse primer, and with spleen DNA from mouse 51 or MT-2 cell
DNA as the template (Fig. 5a). If the
integrated HTLV-1 provirus sequence as shown in Fig. 3 or 4 originated
from the spleen DNA of mouse 51, the PCR would yield a 215-bp DNA
fragment from the spleen DNA of mouse 51 but not from the MT-2 cell
DNA. The results show that the expected band was observed from one of
the three DNA samples from the spleen of mouse 51 (Fig. 5b) and that
its DNA sequence was identical to the previously cloned 59-bp flanking
sequence (Fig. 4) and to 156 bp of 3' LTR.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
HTLV-1 3' LTR and flanking cellular sequence identified
from the spleen DNA of mouse 51 by linker-mediated PCR and DNA cloning.
It is composed of 3' LTR (nucleotides [nt] 1 to 118; 118 bp),
flanking cellular sequence (nt 119 to 177; 58 bp), and linker sequence
(nt 178 to 198; 21 bp).
|
|

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 4.
Identification of 3' LTR flanking sequence in spleen DNA
from mouse 51 as being of mouse genome origin. (a) Oligonucleotides
used for PCR as a primer set (51F and 51R) and probe (51P). (b) Results
of PCR for detection of the predicted 59-bp fragment by using 0.16 µg
of DNA from MT-2 cells or from normal mouse spleen (NSP) as the
template. Ten microliters of each PCR product was electrophoresed in a
2% agarose gel, followed by ethidium bromide staining (left panel).
Southern hybridization was carried out with probe 51P (right panel).
|
|

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 5.
Direct PCR amplification of the integration site
composed of HTLV-1 3' LTR and flanking cellular sequence in spleen DNA
from mouse 51 (51sp). (a) PCR using Bio-2 (a portion of 3' LTR of
HTLV-1 provirus; nt 8899 to 8922) and 51R (flanking sequence of spleen
DNA from mouse 51 [Fig. 4, nt 177 to 158]) as primers should generate
a 215-bp fragment (Fig. 3). (b) Results of three independent
experiments using 1 µg of spleen DNA from mouse 51 in each PCR; the
PCR products were separated in an agarose gel. Shown are results from
ethidium bromide staining (left panel) and the corresponding Southern
hybridization with probe 51P (right panel). M, DNA size markers
indicating 299, 200, and 101 bp.
|
|
Detection of antibody response.
An antibody titer of 16-fold
or more by the particle agglutination method was considered positive.
Antibodies against HTLV-1 antigens were not detected in the plasma of
any of the 18 C3H/HeJ mice at the ages of 7 to 15 weeks (Table 1).
Histological findings for the HTLV-1 carrier mice.
No abnormal
histological finding was observed in the thymus, lung, heart, liver,
spleen, kidney, stomach, small intestine, colon, peritoneal lymph
nodes, ovary, or uterus for the MT-2 cell-injected mice (data not
shown).
RT-PCR analysis of pX mRNA.
One-half microgram of
mouse RNA containing RNA from 10 to 100 MT-2 cells was detected by
RT-PCR, as revealed by ethidium bromide staining on an agarose gel.
However, 1/2 µg of RNA from the spleen of each of three mice examined
did not show the corresponding signal on agarose gel electrophoresis.
Analysis of the infected cell types in the spleen.
The
splenocytes were fractionated into T-cell and B-cell fractions by a
cell sorter. Three of four tubes of T-cell fraction from mouse 2 and
one of two tubes of T-cell fraction from mouse 3 showed the presence of
pX sequence. Four tubes of B-cell fraction and one tube of
non-T, non-B fraction from mouse 2, and two tubes of B-cell fraction
from mouse 3, did not show the presence of pX sequence (Fig.
6).

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 6.
Detection of HTLV-1 pX sequence in T-cell
fraction of splenocytes from MT-2 cell-injected C3H/HeJ mice. Four
aliquots of T-cell and B-cell fractions and one aliquot of non-T, non-B
fraction from mouse 2 (2T, 2B, and 2 , respectively), as well as four
aliquots of T-cell and B-cell fractions from mouse 3 (3T and 3B,
respectively) were analyzed. Each lane shows an independent aliquot of
T-cell and B-cell fractions. N, negative control (normal rat PBMC
lysate); P, positive control (the cell lysate equivalent to 100 ATL-1K
cells was diluted with the lysate equivalent to 105 normal
rat PBMC). A rat c-myc fragment of 345 bp could also be
amplified with the primer set that was used for mouse c-myc.
M, DNA size markers indicating 502, 398, 299, and 200 bp.
|
|
 |
DISCUSSION |
We detected HTLV-1 provirus sequence in DNA of PBMC and several
organs in C3H/HeJ mice that received injections with HTLV-1-producing human T cells. The quantitation of HTLV-1 provirus by PCR and statistical analyses of the spleen DNA from the mice strongly suggested
that the HTLV-1 provirus was derived from infected mouse cells, not
from contamination from MT-2 cells remaining in the mouse spleen.
Furthermore, we directly identified a flanking sequence of the proviral
integration site from the spleen DNA of a mouse and demonstrated that
the flanking sequence was the mouse genomic sequence. These results
show that HTLV-1 transmission occurred from MT-2 cells to mouse cells
in vivo, demonstrating that mice can be infected by HTLV-1.
The rate of detection of HTLV-1 provirus in the HTLV-1-injected C3H/HeJ
mice was higher in the spleen and lymph nodes than in PBMC. These
results suggest that the susceptible cells are enriched in the spleen
or the lymph nodes or that the infected cells have tropism to the
lymphatic tissues. The analysis of the cell types in the spleen in
HTLV-1-infected mice showed that the T-cell fraction gave the positive
PCR band of HTLV-1 pX sequence. This is consistent with the
notion that HTLV-1 is a T-lymphotropic virus. We are now analyzing
whether other types of cells are also infected in this mouse system,
since we could find the provirus in the lung and other tissues but not
in the spleen in some of the mice (Table 2), and previous reports also
showed infection of cell types other than T cells in vitro
(23).
The level of provirus as high as 1 molecule in 104 spleen
cells, as shown in spleen DNA from mouse 33, indicates efficient replication and infection in mouse cells. However, there is no detectable antibody to HTLV-1 antigens in the mice. Three possibilities may be considered. First, the viral antigens might not be persistently expressed. RT-PCR showed that there was negligible mRNA for
pX in the spleen cells of the infected mice. This result,
together with flanking sequence data showing two proviruses with
identical integration sites in DNA from the spleen of mouse 51, was
consistent with the possibility that this virus replicates mainly by
cell division rather than by viral gene expression leading to viral amplification like human immunodeficiency virus type 1 (HIV-1) (41). Second, MT-2 cells were injected within 24 h
after birth. This might make the mouse tolerant to HTLV-1 antigens
expressed in MT-2 cells at the time of injection. Third, the host
strain, C3H/HeJ, is known to have a low level of response to antigens such as bacterial lipopolysaccharide (2). In another set of experiments, in which BALB/c mice were similarly injected with MT-2
cells, anti-HTLV-1 antibodies were detected in the plasma of four of
eight BALB/c mice at the age of 12 weeks (data not shown). However,
further study is required to clarify the precise mechanisms of
different antibody responses in different mouse strains.
There have been no reports to date of HTLV-1 infection in mice. In in
vitro experiments, mouse cell lines have been shown to be resistant to
vesicular stomatitis virus pseudotypes bearing HTLV-1 envelope
glycoproteins or to HTLV-1-induced syncytium formation (33).
Thus, mouse cell lines were suggested to be devoid of HTLV-1 receptor.
Our data show HTLV-1 transmission in mice. It is possible that cells in
vivo express variable numbers of HTLV-1 receptor or coreceptors,
although most mouse cell lines may express less. Our in vivo data are
consistent with the recent report that some mouse cell lines are
susceptible, from a study using a sophisticated pseudotype virus of
HIV(HTLV-1) (35).
The low level of expression of HTLV-1 antigen or mRNA has been well
observed in carriers and patients with ATL (16, 23); however, the mechanism by which viral expression in vivo is inhibited is still an enigma. It has been reported that PBMC derived from ATL
patients expressed HTLV-1 antigen only when they were cultured in vitro
(8, 9). Therefore, the demonstration of HTLV-1 antigen
expression in an ex vivo culture is necessary to establish a useful
model system for HTLV-1 pathogenesis.
 |
ACKNOWLEDGMENTS |
J. Fang and S. Kushida contributed equally to this work.
We thank H. Takahashi for his advice in statistical analysis and H. Nakauchi, Y. Matsuzaki, and Y. Takahama for suggestions. We also thank
T. Mogi for histological preparations of mice organs, and Y. Morita and
N. Arashi for technical assistance.
This work was supported in part by a Grant-in-Aid for the 2nd Term of
the Comprehensive 10-Year Strategy for Cancer Control and Cancer
Research from the Ministry of Health and Welfare of Japan and by a
special grant for scientific research from the University of Tsukuba.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Biochemistry and Molecular Oncology, Institute of Basic Medical
Sciences and Center for Tsukuba Advanced Research Alliance, University of Tsukuba, Tsukuba, Ibaraki 305, Japan. Phone: 81-298-53-3272. Fax:
81-298-53-3271. E-mail: m-miwa{at}md.tsukuba.ac.jp.
 |
REFERENCES |
| 1.
|
Akagi, T.,
I. Takeda,
T. Oka,
Y. Ohtsuki,
S. Yano, and I. Miyoshi.
1985.
Experimental infection of rabbits with human T-cell leukemia virus type I.
Jpn. J. Cancer Res.
76:86-94[Medline].
|
| 2.
|
Coutinho, A.
1976.
Genetic control of B-cell responses. II. Identification of the spleen B-cell defect in C3H/HeJ mice.
Scand. J. Immunol.
5:129-140[Medline].
|
| 3.
|
Dietrich, W. F.,
J. Miller,
R. Steen,
M. A. Merchant,
D. Damron-Boles,
Z. Husain,
R. Dredge,
M. J. Daly,
K. A. Ingalls,
T. J. O'Connor,
C. A. Evans,
M. M. DeAngelis,
D. M. Levinson,
L. Kruglyak,
N. Goodman,
N. G. Copeland,
N. A. Jenkins,
T. L. Hawkins,
L. Stein,
D. C. Page, and E. S. Lander.
1996.
A comprehensive genetic map of the mouse genome.
Nature
380:149-152[Medline].
|
| 4.
|
Fang, J.,
S. Kushida,
R. Feng,
M. Tanaka,
H. Kikukawa,
T. Kawamura,
K. Uchida, and M. Miwa.
1997.
Integration of HTLV-1 provirus into mouse transforming growth factor- gene.
Biochem. Biophys. Res. Commun.
233:792-795[Medline].
|
| 5.
|
Franchini, G.
1995.
Molecular mechanism of human T-cell leukemia/lymphotropic virus type I infection.
Blood
86:3619-3639[Free Full Text].
|
| 6.
|
Gessain, A.,
J. C. Vernant,
L. Maurs,
F. Barin,
O. Gout,
A. Calendar, and G. de Thé.
1985.
Antibodies to human T-lymphotrophic virus type-I in patients with tropical spastic paraparesis.
Lancet
ii:407-409.
|
| 7.
|
Hino, S.,
K. Yamaguchi,
S. Katamine,
H. Sugiyama,
T. Amagasaki,
K. Kinoshita,
Y. Yoshida,
H. Doi,
Y. Tsuji, and T. Miyamoto.
1985.
Mother-to-child transmission of human T-cell leukemia virus type-I.
Jpn. J. Cancer Res.
76:474-480[Medline].
|
| 8.
|
Hinuma, Y.,
K. Nagata,
M. Hanaoka,
M. Nakai,
M. Matsumoto,
T. Kinoshita,
S. Shirakawa, and I. Miyoshi.
1981.
Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera.
Proc. Natl. Acad. Sci. USA
78:6476-6480[Abstract/Free Full Text].
|
| 9.
|
Hoshino, H.,
H. Esumi,
M. Miwa,
M. Shimoyama,
K. Minato,
K. Tobinai,
M. Hirose,
S. Watanabe,
N. Inada,
K. Kinoshita,
S. Kamihira,
M. Ichimaru, and T. Sugimura.
1983.
Establishment and characterization of 10 cell lines derived from patients with adult T-cell leukemia.
Proc. Natl. Acad. Sci. USA
80:6061-6065[Abstract/Free Full Text].
|
| 10.
|
Ikeda, M.,
R. Fujino,
T. Matsui,
T. Yoshida,
H. Komoda, and J. Imai.
1984.
A new agglutination test for serum antibodies to adult T-cell leukemia virus.
Gann
75:845-848[Medline].
|
| 11.
|
Ishiguro, N.,
M. Abe,
K. Seto,
H. Sakurai,
H. Ikeda,
A. Wakisaka,
T. Togashi,
M. Tateno, and T. Yoshiki.
1992.
A rat model of human T lymphocyte virus type I (HTLV-I) infection. 1. Humoral antibody response, provirus integration, and HTLV-I-associated myelopathy/tropical spastic paraparesis-like myelopathy in seronegative HTLV-I carrier rats.
J. Exp. Med.
176:981-989[Abstract/Free Full Text].
|
| 12.
|
Jordan, E., and F. S. Collins.
1996.
A march of genetic maps.
Nature
380:111-112[Medline].
|
| 13.
|
Kamihira, S.,
S. Nakashima,
Y. Oyakawa,
Y. Moriuti,
M. Ichimaru,
H. Okuda,
M. Kanamura, and T. Oota.
1987.
Transmission of human T cell lymphotropic virus type I by blood transfusion before and after mass screening of sera from seropositive donors.
Vox Sang.
52:43-44[Medline].
|
| 14.
|
Kawano, F.,
K. Yamaguchi,
H. Nishimura,
H. Tsuda, and K. Takatsuki.
1985.
Variation in the clinical courses of adult T-cell leukemia.
Cancer
55:851-856[Medline].
|
| 15.
|
Kinoshita, K.,
K. Yamanouchi,
S. Ikeda,
S. Momita,
T. Amagasaki,
H. Soda,
M. Ichimaru,
R. Moriuchi,
S. Katamine,
T. Miyamoto, and S. Hino.
1985.
Oral infection of a common marmoset with human T-cell leukemia virus type-I (HTLV-I) by inoculating fresh human milk of HTLV-I carrier mothers.
Jpn. J. Cancer Res.
76:1147-1153[Medline].
|
| 16.
|
Kinoshita, T.,
M. Shimoyama,
K. Tobinai,
M. Ito,
S. Ito,
S. Ikeda,
K. Tajima,
K. Shimotohno, and T. Sugimura.
1989.
Detection of mRNA for the tax1/rex1 gene of human T-cell leukemia virus type I in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carriers by using the polymerase chain reaction.
Proc. Natl. Acad. Sci. USA
86:5620-5624[Abstract/Free Full Text].
|
| 17.
|
Kobayashi, N.,
H. Konishi,
H. Sabe,
K. Shigesada,
T. Noma,
T. Honjo, and M. Hatanaka.
1984.
Genomic structure of HTLV (human T-cell leukemia virus): detection of defective genome and its amplification in MT-2 cells.
EMBO J.
3:1339-1343[Medline].
|
| 18.
|
Kotani, S.,
S. Yoshimoto,
K. Yamato,
M. Fujishita,
M. Yamashita,
Y. Ohtsuki,
H. Taguchi, and I. Miyoshi.
1986.
Serial transmission of human T-cell leukemia virus type I by blood transfusion in rabbits and its prevention by use of X-irradiated stored blood.
Int. J. Cancer
37:843-847[Medline].
|
| 19.
|
Kushida, S.,
N. Maeda,
J. Fang,
K. Uchida, and M. Miwa.
1995.
Establishment of HTLV-1 carrier mice by injection with HTLV-1-producing T cells, abstr., p. 86.
In
Abstracts of the 18th Symposium, Leukemia and Lymphoma/Pathogenesis and Treatment/Molecular Aspects. International Association for Comparative Research on Leukemia and Related Diseases, Kyoto, Japan.
|
| 20.
|
Kushida, S.,
H. Mizusawa,
M. Matsumura,
H. Tanaka,
Y. Ami,
M. Hori,
K.-I. Yagami,
T. Kameyama,
Y. Tanaka,
A. Yoshida,
H. Nyunoya,
K. Shimotohno,
Y. Iwasaki,
K. Uchida, and M. Miwa.
1994.
High incidence of HAM/TSP-like symptoms in WKA rats after administration of human T-cell leukemia virus type 1-producing cells.
J. Virol.
68:7221-7226[Abstract/Free Full Text].
|
| 21.
|
Kushida, S.,
M. Matsumura,
H. Tanaka,
Y. Ami,
M. Hori,
M. Kobayashi,
K. Uchida,
K. Yagami,
T. Kameyama,
T. Yoshizawa,
H. Mizusawa,
Y. Iwasaki, and M. Miwa.
1993.
HTLV-1-associated myelopathy/tropical spastic paraparesis-like rats by intravenous injection of HTLV-1-producing rabbit or human T-cell line into adult WKA rats.
Jpn. J. Cancer Res.
84:831-833[Medline].
|
| 22.
|
Matsumura, M.,
S. Kushida,
Y. Ami,
K. Uchida,
T. Kameyama,
A. Terano,
H. Shiraki,
H. Sato, and M. Miwa.
1992.
A simple and reliable method for the detection and quantitation of the human T-cell leukemia virus type-I provirus in peripheral blood mononuclear cells of seropositive blood donors.
Jpn. J. Clin. Oncol.
22:335-341.
|
| 23.
|
Miwa, M.
1990.
Mechanism of oncogenesis of adult T-cell leukemia/lymphoma.
Hematol. Rev.
3:247-255.
|
| 24.
|
Miyoshi, I.,
I. Kubonishi,
S. Yoshimoto,
T. Akagi,
Y. Ohtsuki,
Y. Shiraishi,
K. Nagata, and Y. Hinuma.
1981.
Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells.
Nature
294:770-771[Medline].
|
| 25.
|
Mochizuki, M.,
T. Watanabe,
K. Yamaguchi,
K. Takatsuki,
K. Yoshimura,
M. Shirao,
S. Nakashima,
S. Mori,
S. Araki, and N. Miyata.
1992.
HTLV-I uveitis: a distinct clinical entity caused by HTLV-I.
Jpn. J. Cancer Res.
83:236-239[Medline].
|
| 26.
|
Nishioka, K.,
I. Maruyama,
K. Sato,
I. Kitajima,
Y. Nakajima, and M. Osame.
1989.
Chronic inflammatory arthropathy associated with HTLV-I.
Lancet
i:441.
|
| 27.
|
O'Connell, C. D., and M. Cohen.
1984.
The long terminal repeat sequences of a novel human endogenous retrovirus.
Science
226:1204-1206[Abstract/Free Full Text].
|
| 28.
|
Osame, M.,
M. Matsumoto,
K. Usuku,
S. Izumo,
N. Ijichi,
H. Amitani,
M. Tara, and A. Igata.
1987.
Chronic progressive myelopathy associated with elevated antibodies to HTLV-1 and adult T-cell leukemia cells.
Ann. Neurol.
21:117-122[Medline].
|
| 29.
|
Poiesz, B. J.,
F. W. Ruscetti,
A. F. Gazdar,
P. A. Bunn,
J. D. Minna, and R. C. Gallo.
1980.
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.
Proc. Natl. Acad. Sci. USA
77:7415-7419[Abstract/Free Full Text].
|
| 30.
|
Robert-Guroff, M.,
Y. Nakao,
K. Notake,
Y. Ito,
A. Sliski, and R. C. Gallo.
1982.
Natural antibodies to human retrovirus HTLV-I in a cluster of Japanese patients with adult T-cell leukemia.
Science
215:975-978[Abstract/Free Full Text].
|
| 31.
|
Sato, K.,
I. Maruyama,
Y. Maruyama,
I. Kitajima,
Y. Nakajima,
M. Higaki,
K. Yamamoto,
N. Miyasaka,
M. Osame, and K. Nishioka.
1991.
Arthritis in patients infected with human T lymphotropic virus type I.
Arthritis Rheum.
34:714-721[Medline].
|
| 32.
|
Seto, A.,
T. Isono, and K. Ogawa.
1991.
Infection of inbred rabbits with cell-free HTLV-I.
Leuk. Res.
15:105-110[Medline].
|
| 33.
|
Sommerfelt, M. A.,
B. P. Williams,
P. R. Clapham,
E. Solomon,
P. N. Goodfellow, and R. A. Weiss.
1988.
Human T cell leukemia viruses use a receptor determined by human chromosome 17.
Science
242:1557-1559[Abstract/Free Full Text].
|
| 34.
|
Suga, T.,
T. Kameyama,
T. Kinoshita,
K. Shimotohno,
M. Matsumura,
H. Tanaka,
S. Kushida,
Y. Ami,
M. Uchida,
K. Uchida, and M. Miwa.
1991.
Infection of rats with HTLV-1: a small animal model for HTLV-1 carriers.
Int. J. Cancer
49:764-769[Medline].
|
| 35.
|
Sutton, R. E., and D. R. Littman.
1996.
Broad host range of human T-cell leukemia virus type 1 demonstrated with an improved pseudotyping system.
J. Virol.
70:7322-7326[Abstract/Free Full Text].
|
| 36.
|
Tajima, K.,
The T and B Cell Malignancy Study Group, et al.
1990.
The 4th nationwide study of adult T cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features.
Int. J. Cancer
45:237-243[Medline].
|
| 37.
|
Tajima, K.,
S. Tominaga,
T. Suchi,
T. Kawagoe,
H. Komoda,
Y. Hinuma,
T. Oda, and K. Fujita.
1982.
Epidemiological analysis of the distribution of antibody to adult T-cell leukemia virus-associated antigen: possible horizontal transmission of adult T-cell leukemia virus.
Gann
73:893-901[Medline].
|
| 38.
| Takatsuki, K., K. Yamaguchi, F. Kawano, T. Hattori, H. Nishimura, H. Tsuda, I. Sanada, K. Nakada, and Y. Itai. 1985. Clinical diversity in adult T-cell leukemia-lymphoma. Cancer Res.
45(Suppl.):4644S-4645S.
|
| 39.
|
Uchiyama, T.,
J. Yodoi,
K. Sagawa,
K. Takatsuki, and H. Uchino.
1977.
Adult T-cell leukemia: clinical and hematologic features of 16 cases.
Blood
50:481-492[Free Full Text].
|
| 40.
|
Uemura, Y.,
S. Kotani,
S. Yoshimoto,
M. Fujishita,
M. Yamashita,
Y. Ohtsuki,
H. Taguchi, and I. Miyoshi.
1987.
Mother-to-offspring transmission of human T cell leukemia virus type I in rabbits.
Blood
69:1255-1258[Abstract/Free Full Text].
|
| 41.
|
Wattel, E.,
J.-P. Vartanian,
C. Pannetier, and S. Wain-Hobson.
1995.
Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy.
J. Virol.
69:2863-2868[Abstract].
|
| 42.
|
Yamamoto, N.,
M. Hayami,
A. Komuro,
J. Schneider,
G. Hunsmann,
M. Okada, and Y. Hinuma.
1984.
Experimental infection of cynomolgus monkeys with a human retrovirus, adult T-cell leukemia virus.
Med. Microbiol. Immunol.
172:57-64.
|
| 43.
|
Yamanouchi, K.,
K. Kinoshita,
R. Moriuchi,
S. Katamine,
T. Amagasaki,
S. Ikeda,
M. Ichimaru,
T. Miyamoto, and S. Hino.
1985.
Oral transmission of human T-cell leukemia virus type-I into a common marmoset (Callithrix jaccus) as an experimental model for milk-borne transmission.
Jpn. J. Cancer Res.
76:481-487[Medline].
|
| 44.
|
Yoshida, M.,
M. Seiki,
K. Yamaguchi, and K. Takatsuki.
1984.
Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease.
Proc. Natl. Acad. Sci. USA
81:2534-2537[Abstract/Free Full Text].
|
| 45.
|
Yoshioka, R.,
K. Yamaguchi,
T. Yoshinaga, and K. Takatsuki.
1985.
Pulmonary complications in patients with adult T-cell leukemia.
Cancer
55:2491-2494[Medline].
|
J Virol, May 1998, p. 3952-3957, Vol. 72, No. 5
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Takayanagi, R., Ohashi, T., Yamashita, E., Kurosaki, Y., Tanaka, K., Hakata, Y., Komoda, Y., Ikeda, S., Tsunetsugu-Yokota, Y., Tanaka, Y., Shida, H.
(2007). Enhanced Replication of Human T-Cell Leukemia Virus Type 1 in T Cells from Transgenic Rats Expressing Human CRM1 That Is Regulated in a Natural Manner. J. Virol.
81: 5908-5918
[Abstract]
[Full Text]
-
Marques, S. M. P., Veyrune, J.-L., Shukla, R. R., Kumar, A.
(2003). Restriction of Human Immunodeficiency Virus Type 1 Rev Function in Murine A9 Cells Involves the Rev C-Terminal Domain. J. Virol.
77: 3084-3090
[Abstract]
[Full Text]
-
Delebecque, F., Pramberger, K., Prevost, M.-C., Brahic, M., Tangy, F.
(2002). A Chimeric Human T-Cell Lymphotropic Virus Type 1 with the Envelope Glycoprotein of Moloney Murine Leukemia Virus Is Infectious for Murine Cells. J. Virol.
76: 7883-7889
[Abstract]
[Full Text]
-
Hakata, Y., Yamada, M., Shida, H.
(2001). Rat CRM1 Is Responsible for the Poor Activity of Human T-Cell Leukemia Virus Type 1 Rex Protein in Rat Cells. J. Virol.
75: 11515-11525
[Abstract]
[Full Text]
-
Tanaka, M., Sun, B., Fang, J., Nitta, T., Yoshida, T., Kohtoh, S., Kikukawa, H., Hanai, S., Uchida, K., Miwa, M.
(2001). Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection of Mice: Proliferation of Cell Clones with Integrated HTLV-1 Provirus in Lymphoid Organs. J. Virol.
75: 4420-4423
[Abstract]
[Full Text]
-
Twizere, J.-C., Kerkhofs, P., Burny, A., Portetelle, D., Kettmann, R., Willems, L.
(2000). Discordance between Bovine Leukemia Virus Tax Immortalization In Vitro and Oncogenicity In Vivo. J. Virol.
74: 9895-9902
[Abstract]
[Full Text]